CAIRO – The Ministry of Public Business Sector announced that the Holding Company for Pharmaceuticals, Chemicals and Medical Supplies is targeting a consolidated revenue increase to LE18 billion in its budget plan for FY 2025/2026 with a 131% growth compared to FY 2023/2024.
Net profits are expected to rise to LE3.4 billion with an increase of 343%, alongside notable improvements in the market value of its listed subsidiaries.
This came during a meeting of the general of the company chaired by Minister of Public Business Sector Mohammed el-Shemi to approve the budget plan for FY 2025/2026.
The meeting was attended by the company’s board of directors led by Ahmed Hegazy, members of the general assembly and representatives from the Central Auditing Organisation.
During the meeting, all budget plans for holding companies and their subsidiaries for the new fiscal year have been finalised.
In a statement on Tuesday, Shemi asserted that the pharmaceutical industry is a vital pillar of public health security and a key contributor to the national economy.
He stressed that the development and expansion of pharmaceutical companies under the ministry’s umbrella is a strategic objective.
He added that the ministry is actively working on localizing and deepening pharmaceutical manufacturing, adopting and applying cutting-edge global manufacturing technologies to enhance product quality and boost competitiveness in local, regional and international markets.
He said that the development projects include modernizing production lines, increasing manufacturing capacities and adhering to the highest standards of sustainability, quality and Good Manufacturing Practices (GMP). This also includes ensuring occupational health and safety, and optimising the use of assets and available resources.
The minister stressed that human capital development is a cornerstone in achieving these targets, with specialised training and capacity-building programs that promote innovation and advance pharmaceutical research.
These efforts aim to produce high-value, strategic pharmaceutical products, accelerate project timelines and enhance partnerships with local and international private sector players, thereby increasing production and export capabilities and expanding into new markets, he said.
Shemi noted that the ministry prioritises financial restructuring of its subsidiaries to ensure sustainable profitability and provide the resources needed for production expansion.
